Obinutuzumab (Gazyvaro)
Gazyvaro is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy.
In 271 adults with active lupus nephritis on mycophenolate and prednisone, obinutuzumab gave more complete renal responses at week 76 than placebo (46.4% vs 33.1%; difference 13.4 points), with more serious adverse events, mainly infections and COVID-19. RCT · phase 3 · n = 271 · N Engl J Med · 2025
In 303 adults with active SLE without proliferative or membranous nephritis on standard therapy, obinutuzumab gave more SRI-4 responses at week 52 than placebo (76.7% vs 53.5%; P<0.001). Serious adverse events: 15.9% vs 11.9%. RCT · phase 3 · n = 303 · N Engl J Med · 2026